Challenges to Response-Guided Therapy and Stopping Rules (Course CG.11)
Published on July 11, 2012 Webcast
Published on July 11, 2012 Webcast
Are you confident in applying response-guided therapy to your patients with chronic hepatitis C undergoing boceprevir- or telaprevir-based triple therapy? Do you know which patients are eligible? Do you know how the rules vary between therapies? In this case-based webcast, Elizabeth Goacher, PA, and Steven L. Flamm, MD, will show you how to apply response-guided therapy and stopping rules in clinical practice. “Challenges to Response-Guided Therapy and Stopping Rules,” is part of the HCV Care and Guidance: Practical Education and Resources.
Steven L. Flamm, MD
- Professor of Medicine and Surgery Division of
- Gastroenterology and Hepatology
- Northwestern University Feinberg School of
- Medicine Chicago, Illinois
Elizabeth K. Goacher, PA-C
- Physician Assistant
- Department of Medicine
- Duke University Medical Center
- Durham, North Carolina
Elizabeth K. Goacher, PA-C, has received honoraria from Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated and; has received consulting fees from Bayer/Onyx, Gilead Sciences, Inc, and Salix Pharmaceuticals
Jill Y. Chang, PA-C, has disclosed no significant relationships.
Steven L. Flamm, MD, has received salary/honoraria, consulting fees, and research support from Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated.
Elizabeth K. Goacher, PA-C, has received honoraria from Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Bayer/Onyx, Gilead Sciences, Inc, and Salix Pharmaceuticals
Cheryl D. Levine, PhD, FNP, has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Vertex Pharmaceuticals Incorporated; and has conducted contracted research for Abbott, Achillion Pharmaceuticals, Inc, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Genentech Inc, Gilead Sciences, Inhibitex, Inc, Medtronic, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Vertex Pharmaceuticals Incorporated, and ZymoGenetics.
Tiffany A. Taskaya, PA-C, CCRC, has received honoraria from Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co, Inc. and Vertex Pharmaceuticals Incorporated.
Available for CME/CE:
Physicians
Publish Date: Jul 11, 2012 Termination Date: Jul 10, 2013Nurses
Publish Date: Jul 11, 2012 Termination Date: Jul 10, 2013Pharmacists
Publish Date: Jul 11, 2012 Termination Date: Jul 10, 2013Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 1.0 hour
Target Audience
This CME/CE activity have been designed for nurses, nurse practitioners, physician assistants, hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, internists, family medicine physicians, and pharmacists involved in the care of patients with HCV.
Activity Goal
The goal of this activity is to address the needs of nurse practitioners, physician assistants, hepatologists, gastroenterologists, and pharmacists for information and practical instruction regarding new direct-acting antiviral (DAA) therapies for hepatitis C and their integration into clinical practice.
Learning Objective (s)
- Assess requirements for response-guided therapy and stopping rules when administering direct-acting antiviral (DAA) anti-HCV therapy in clinical practice.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 1.00 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1590-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Steven L. Flamm, MD has received salary/honoraria, consulting fees, and research support from Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated. This activity will include discussion of unlabeled use of anti-HCV therapies.
Elizabeth K. Goacher, PA-C has received honoraria from Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated and; has received consulting fees from Bayer/Onyx, Gilead Sciences, Inc, and Salix Pharmaceuticals
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA Medical Writer, has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Sherilyn C. Brinkley, MSN, CRNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated.
Jill Y. Chang, PA-C has disclosed no significant relationships.
Steven L. Flamm, MD has received salary/honoraria, consulting fees, and research support from Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated.
Elizabeth K. Goacher, PA-C has received honoraria from Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Bayer/Onyx, Gilead Sciences, Inc, and Salix Pharmaceuticals
Cheryl D. Levine, PhD, FNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Vertex Pharmaceuticals Incorporated; and has conducted contracted research for Abbott, Achillion Pharmaceuticals, Inc, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Genentech Inc, Gilead Sciences, Inhibitex, Inc, Medtronic, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Vertex Pharmaceuticals Incorporated, and ZymoGenetics.
Tiffany A. Taskaya, PA-C, CCRC has received honoraria from Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co, Inc. and Vertex Pharmaceuticals Incorporated.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Jul 11, 2012 Termination Date: Jul 10, 2013Nurses
Publish Date: Jul 11, 2012 Termination Date: Jul 10, 2013Pharmacists
Publish Date: Jul 11, 2012 Termination Date: Jul 10, 2013Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 1.0 hour
Target Audience
This CME/CE activity have been designed for nurses, nurse practitioners, physician assistants, hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, internists, family medicine physicians, and pharmacists involved in the care of patients with HCV.
Activity Goal
The goal of this activity is to address the needs of nurse practitioners, physician assistants, hepatologists, gastroenterologists, and pharmacists for information and practical instruction regarding new direct-acting antiviral (DAA) therapies for hepatitis C and their integration into clinical practice.
Learning Objective (s)
- Assess requirements for response-guided therapy and stopping rules when administering direct-acting antiviral (DAA) anti-HCV therapy in clinical practice.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 1.00 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1590-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Steven L. Flamm, MD has received salary/honoraria, consulting fees, and research support from Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated. This activity will include discussion of unlabeled use of anti-HCV therapies.
Elizabeth K. Goacher, PA-C has received honoraria from Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated and; has received consulting fees from Bayer/Onyx, Gilead Sciences, Inc, and Salix Pharmaceuticals
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA Medical Writer, has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Sherilyn C. Brinkley, MSN, CRNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated.
Jill Y. Chang, PA-C has disclosed no significant relationships.
Steven L. Flamm, MD has received salary/honoraria, consulting fees, and research support from Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated.
Elizabeth K. Goacher, PA-C has received honoraria from Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Bayer/Onyx, Gilead Sciences, Inc, and Salix Pharmaceuticals
Cheryl D. Levine, PhD, FNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Vertex Pharmaceuticals Incorporated; and has conducted contracted research for Abbott, Achillion Pharmaceuticals, Inc, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Genentech Inc, Gilead Sciences, Inhibitex, Inc, Medtronic, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Vertex Pharmaceuticals Incorporated, and ZymoGenetics.
Tiffany A. Taskaya, PA-C, CCRC has received honoraria from Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co, Inc. and Vertex Pharmaceuticals Incorporated.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Are you confident in applying response-guided therapy to your patients with chronic hepatitis C undergoing boceprevir- or telaprevir-based triple therapy? Do you know which patients are eligible? Do you know how the rules vary between therapies? In this case-based webcast, Elizabeth Goacher, PA, and Steven L. Flamm, MD, will show you how to apply response-guided therapy and stopping rules in clinical practice. “Challenges to Response-Guided Therapy and Stopping Rules,” is part of the HCV Care and Guidance: Practical Education and Resources.





